FDA Approval for TOUJEO SOLOSTAR issued to SANOFI US SERVICES

$SNY
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $SNY alert in real time by email
Biologic License Application (BLA): 206538
Company: SANOFI US SERVICES
Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
TOUJEO MAX SOLOSTAR INSULIN GLARGINE RECOMBINANT 900 UNITS/3ML (300 UNITS/ML) SOLUTION;SUBCUTANEOUS Prescription None No No
TOUJEO SOLOSTAR INSULIN GLARGINE RECOMBINANT 450 UNITS/1.5ML (300 UNITS/ML) SOLUTION;SUBCUTANEOUS Prescription None No No
Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
02/25/2015 ORIG-1 Approval N/A Label (PDF)
Letter (PDF)
Review
Summary Review (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206538s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/206538Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206538Orig1s000TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206538Orig1s000SumR.pdf
Supplements
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
08/29/2024 SUPPL-17 Supplement Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/206538Orig1s017Lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/206538Orig1s017ltr.pdf
08/16/2022 SUPPL-16 Supplement Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206538s016lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/206538Orig1s016ltr.pdf
11/15/2019 SUPPL-14 Supplement Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206538s013s014lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/021081Orig1s073, s074; 021629Orig1s039, s040; 206538Orig1s013, s014ltr.pdf
11/15/2019 SUPPL-13 Supplement Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206538s013s014lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/021081Orig1s073, s074; 021629Orig1s039, s040; 206538Orig1s013, s014ltr.pdf
11/26/2019 SUPPL-12 Supplement Label (PDF)
Label (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/206538Orig1s012ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206538s012lbl.pdf
10/25/2018 SUPPL-11 Supplement Label (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206538s010s011lbl.pdf
10/25/2018 SUPPL-10 Supplement Label (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206538s010s011lbl.pdf
03/26/2018 SUPPL-6 Supplement Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206538s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/206538Orig1s006ltr.pdf
11/23/2016 SUPPL-3 Supplement

Label is not available on this site.

02/16/2016 SUPPL-2 Supplement

Label is not available on this site.

09/29/2015 SUPPL-1 Supplement Letter (PDF)

Label is not available on this site.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206538s001lbl.pdf
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
Patient Package Insert
Note Url
08/29/2024 SUPPL-17 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/206538Orig1s017Lbl.pdf
08/16/2022 SUPPL-16 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206538s016lbl.pdf
08/16/2022 SUPPL-16 Labeling-Container/Carton Labels Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206538s016lbl.pdf
11/26/2019 SUPPL-12 Efficacy-New Patient Population Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/206538Orig1s012ltr.pdf
11/26/2019 SUPPL-12 Efficacy-New Patient Population Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206538s012lbl.pdf
11/15/2019 SUPPL-14 Labeling-Patient Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206538s013s014lbl.pdf
11/15/2019 SUPPL-14 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206538s013s014lbl.pdf
11/15/2019 SUPPL-13 Labeling-Container/Carton Labels Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206538s013s014lbl.pdf
11/15/2019 SUPPL-13 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206538s013s014lbl.pdf
10/25/2018 SUPPL-11 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206538s010s011lbl.pdf
10/25/2018 SUPPL-11 Labeling-Container/Carton Labels Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206538s010s011lbl.pdf
10/25/2018 SUPPL-10 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206538s010s011lbl.pdf
03/26/2018 SUPPL-6 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206538s006lbl.pdf
03/26/2018 SUPPL-6 Labeling-Container/Carton Labels Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206538s006lbl.pdf
03/26/2018 SUPPL-6 Labeling-Patient Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206538s006lbl.pdf
02/25/2015 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206538s000lbl.pdf
Get the next $SNY alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SNY

DatePrice TargetRatingAnalyst
7/26/2024$55.00 → $60.00Buy
Argus
1/23/2024$55.00Equal-Weight
Morgan Stanley
1/16/2024Buy
UBS
12/5/2023Overweight → Neutral
JP Morgan
10/30/2023Buy → Hold
Stifel
9/6/2023Hold → Buy
Berenberg
7/14/2023Buy
HSBC Securities
4/28/2023Hold → Sell
Deutsche Bank
More analyst ratings

$SNY
Press Releases

Fastest customizable press release news feed in the world

See more
  • Beyfortus® immunization to protect infants from RSV has begun

    Six out of 10 infants and newborns in Canada will have access to the protective antibody Beyfortus® for the first time this seasonAccess to Beyfortus® includes infants in remote communities most impacted by respiratory syncytial virus (RSV), in all three territories and northern Quebec and OntarioBeyfortus® demonstrated the ability to reduce the risk of RSV lower respiratory tract infections by 74.5%, including hospitalizations in infants entering their first RSV seasoniTORONTO, Oct. 28, 2024 /CNW/ - Sanofi is pleased to announce Beyfortus® (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration of

    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals

    US FLUBLOK label1 updated to incorporate new safety study in pregnant individualsNew safety data involving more than 48,000 pregnant individuals published in American Journal of Obstetrics and Gynecology (AJOG) Global ReportsRecombinant or inactivated flu vaccines are recommended by the U.S. Centers for Disease Control and Protection (CDC), Advisory Committee on Immunization Practices (ACIP) and American College of Obstetricians and Gynecologists (ACOG) for individuals who are or will become pregnant during flu season2,3,4Sanofi is committed to the ongoing rigorous scientific study of flu vaccines in at-risk populations, including older patients, patients with comorbidities and pregnant indi

    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Sanofi commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to increase diversity in clinical studies

    BRIDGEWATER, N.J., Oct. 16, 2024 /PRNewswire/ -- Sanofi announced today it will contribute $18 million to three Historically Black Medical Schools to help the institutions work to increase diversity in clinical studies. The investment over 10 years is aimed at strengthening Centers of Excellence in clinical study diversity at Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine. Funding will be used to hire clinical research staff, establish infrastructure such as online chat services and pharmacy upgrades, create customized training programs, and more. Each of the Centers of Excellence have their own specific needs, which will help them harness t

    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SNY
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SNY
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SNY
SEC Filings

See more

$SNY
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

    Submission status for SANOFI-AVENTIS US's drug SOLIQUA 100/33 (SUPPL-14) with active ingredient INSULIN GLARGINE; LIXISENATIDE has changed to 'Approval' on 11/01/2024. Application Category: BLA, Application Number: 208673, Application Classification:

    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for ADLYXIN issued to SANOFI-AVENTIS US

    Submission status for SANOFI-AVENTIS US's drug ADLYXIN (SUPPL-9) with active ingredient LIXISENATIDE has changed to 'Approval' on 11/01/2024. Application Category: BLA, Application Number: 208471, Application Classification:

    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for SARCLISA issued to SANOFI AVENTIS US

    Submission status for SANOFI AVENTIS US's drug SARCLISA (SUPPL-12) with active ingredient ISATUXIMAB-IRFC has changed to 'Approval' on 10/25/2024. Application Category: BLA, Application Number: 761113, Application Classification:

    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SNY
Leadership Updates

Live Leadership Updates

See more
  • I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

    ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

    $AZN
    $IMAB
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Sanofi Bridging the Gap between the Homeless and Society via Futsal

    Sanofi hosted the founding ceremony of the homeless futsal club ‘Dream' and organized a friendly match as a part of the Helping Hands program Sanofi employees and ‘Dream' members interacted through the friendly match Sanofi has carried out social responsibility activities targeting the homeless and housing vulnerable groups since 2011 Sanofi in Korea[1], the Korean subsidiaries of the global healthcare company Sanofi, hosted the founding ceremony of the homeless futsal club ‘Dream' together with Dalpengyee, a nonprofit organization, to promote self-sufficiency among the homeless. At the founding ceremony of the ‘Dream', held in Seongsu-dong, Seoul on the 17th, the club's first game

    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Sanofi appoints new Heads of U.S. General Medicines, and North America Vaccines and Consumer Healthcare

    BRIDGEWATER, N.J., Aug. 3, 2022 /PRNewswire/ -- Sanofi announces three appointments to key leadership roles for U.S. General Medicines and its North American Vaccines and Consumer Healthcare businesses. Olivier Bogillot becomes Head of U.S. General Medicines. Bogillot, most recently President of Sanofi France, will lead the business unit responsible for serving the Diabetes, Cardiovascular and Transplant communities effective September 1. Bogillot joined Sanofi in 2015, and has held various positions within the company, including as Executive Director of Global Policy based in the U.S. and Chief of Staff to the CEO. In March 2020, he was appointed President of Sanofi France, where he has led

    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SNY
Financials

Live finance-specific insights

See more
  • Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024

    ― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024 ― ― Industry veteran, Patrick Horn M.D., Ph.D., appointed as chief medical officer ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, toda

    $FULC
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

    ― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights ― ― Fulcrum will receive an upfront payment of $80.0 million, and is eligible to receive $975.0 million in potential milestones, plus royalties on ex-U.S. product sales; parties will share future global development costs 50:50 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today to discuss the collaboration and other recent corporate developments, in conjunction with the first quarter 2024 financial results ― CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a c

    $FULC
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Novavax Reports First Quarter 2024 Financial Results and Operational Highlights

    Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvantThis agreement represents a potential multi-billion dollar revenue opportunity for Novavax including:$500 million upfront payment Approximately $70 million equity investment in NovavaxUp to $700 million in COVID-19 and combination product near-term milestones, plus ongoing tiered royalties on product salesUp to $200 million in milestones plus royalties for each new vaccine developed utilizing Novavax's Matrix-MTM adjuvantAnnounces addition of standalone influenza vaccine to P

    $NVAX
    $SNY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

$SNY
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more